title: [Dynamics of local expression of connexin-43 and basic fibroblast growth factor receptors in patients with skin and soft-tissue infections against the background of diabetes mellitus type II].
abstract: Clinical results of wound healing dynamics were studied in 60 patients with soft-tissue infection against the background of diabetes mellitus type II. At the same time the study considered indices of intercellular contacts protein tissue expression such as connexin 43 (Cx43) and basic fibroblast growth factor receptors (bFGFR). The basic therapy of biopsy material of wound borders was applied. The reduction of bFGFR expression and the minor growth of Cx43 expression were observed. The pain syndrome proceeded for a long time and there were signs of perifocal inflammation, retard wound healing with granulation tissue. The application of combined method of ozone therapy which included autohemotherapy with ozone and an external management of wound by ozone-oxygen mixture facilitated to considerable shortening of inflammatory phase and regeneration. It was associated with increased Cx43 expression (in 1.9 times) in comparison with initial level and bFGFR was enlarged in 1.7 times to eighth day of postoperative period.
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Vinnik
authors.forename: A B
authors.initials: AB
authors.lastname: Salmina
authors.forename: O V
authors.initials: OV
authors.lastname: Tepliakova
authors.forename: A I
authors.initials: AI
authors.lastname: Drobushevskaia
authors.forename: N A
authors.initials: NA
authors.lastname: Malinovskaia
authors.forename: E A
authors.initials: EA
authors.lastname: Pozhilenkova
authors.forename: A V
authors.initials: AV
authors.lastname: Morgun
authors.forename: A G
authors.initials: AG
authors.lastname: Gitlina
mesh_terms: D018031:Connexin 43 / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004333:Drug Administration Routes; D005260:Female; D006097:Granulation Tissue / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010083:Oxidants, Photochemical / Q000627:therapeutic use; D010126:Ozone / Q000627:therapeutic use*; D019990:Perioperative Care / Q000379:methods; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000378:metabolism*; D012874:Skin Diseases, Infectious / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000601:surgery; D018461:Soft Tissue Infections / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000601:surgery; D013514:Surgical Procedures, Operative / Q000379:methods*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
chemical_list: D018031:Connexin 43; D010083:Oxidants, Photochemical; D010126:Ozone; D051496:Receptor, Fibroblast Growth Factor, Type 1